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B R I E F  R E P O R T
Antimicrobial Susceptibility Trends 
Observed in Urinary Pathogens 
Obtained From New York State
Elliot L. Rank,1 Thomas Lodise,2 Lisa Avery,3 Eve Bankert,4  
Erica Dobson,5 Ghinwa Dumyati,6 Stephen Hassett,7  
Marina Keller,8 Matthew Pearsall,9 Teresa Lubowski,10 and Joseph J. Carreno2,
1Microbiology, Quest Diagnostics, Teterboro, New Jersey; 2Pharmacy Practice, Albany College 
of Pharmacy and Health Sciences, Albany, New York; 3Pharmacy Practice, Wegmans School 
of Pharmacy/St. John Fisher College, Rochester, New York; 4Island Peer Review Organization, 
Albany, New York; 5Pharmacy, University of Rochester Medical Center, Rochester, New York; 
6Infectious Diseases Division, University of Rochester, Rochester, New York; 7Emergency 
Medicine, Albany Med EmUrgent Care, Albany, New York; 8Infectious Disease, Orange 
Regional Medical Center, Middletown, New York; 9Pharmacy, Glens Falls Hospital, Glens Falls, 
New York; 10Island Peer Review Organization, Albany, New York
International guidelines recommend using local susceptibility 
data to direct empiric therapy for acute uncomplicated cystitis. 
We evaluated outpatient urinary isolate susceptibility trends 
in New York State. Nitrofurantoin had the lowest resistance 
prevalence whereas trimethoprim-sulfamethoxazole and fluo-
roquinolones had higher prevalences. This study highlights the 
need for local outpatient antimicrobial stewardship programs.
Keywords. antibiogram; antimicrobial resistance; New 
York State; urinary tract infection.
 
Acute uncomplicated cystitis is a prevalent outpatient condition 
[1, 2]. It is estimated that there are approximately 6–8 million 
annual visits to a physician or clinic by patients for treatment of 
an acute uncomplicated cystitis event [3, 4]. Treatment guide-
lines for acute uncomplicated cystitis in premenopausal, non-
pregnant women are well defined in international guidelines [2]. 
In these international guidelines, empiric treatment recom-
mendations are provided, but these empiric recommendations 
are accompanied by the caveat that empiric antibiotic selection 
should be guided by local organism susceptibility data and 
patient-specific risk factors.
Although treatment selection for acute uncomplicated cyst-
itis was straightforward in the past, management of these con-
ditions has been complicated by reports of rising antibiotic 
resistance rates for several key urinary pathogens. It is impor-
tant to note that much of the data that describe rising rates of 
resistance for uncomplicated cystitis pathogens were derived 
from hospitalized inpatients with urinary tract infections. Data 
that describe outpatient resistance rates are consistent with pub-
lished inpatient reports but are limited [5]. It is also unclear if 
resistance rates among acute uncomplicated cystitis pathogens 
are applicable to all age groups, and to both men and women. 
Given these gaps in the literature, this study sought to describe 
the prevalence and resistance patterns of urinary pathogens in 
New York State in the outpatient setting. The intent was to use 
these data to help inform treatment decisions for patients who 
present with uncomplicated cystitis in the outpatient setting 
and to assess the appropriateness of empiric treatment recom-
mendations found in national guidelines for New York State.
METHODS
A retrospective analysis was conducted on all urine cultures 
received from outpatient settings (defined as physician offices 
or outpatient clinics), with antimicrobial susceptibility test-
ing performed from January 1, 2016, to December 31, 2016, 
at a major clinical microbiology reference laboratory (Quest 
Diagnostics Laboratory, Teterboro, NJ). As antimicrobial test-
ing is not routinely recommended for Streptococcus agalactiae 
and Staphylococcus saprophyticus, these organisms were not 
included in the analysis. Data from 17 New York State counties 
were included in the overall sample (Table  1). Urine cultures 
demonstrating 1 or 2 bacterial isolates at >105 colony-forming 
units/mL were included (only the first reported isolate from 
dual infections was included). In accordance with standards for 
summarizing antimicrobial susceptibilities for antibiograms, 
each species required a minimum of 30 isolates for inclusion in 
antimicrobial susceptibility estimates.
Urine pathogens were isolated from bi-plates of Trypticase 
Soy Agar with 5% Sheep Blood (TSA II) and MacConkey II 
Agar, followed by identification and automated drug susceptibil-
ity testing (Vitek-2). Antimicrobials tested included ampicillin, 
ceftazidime, cefazolin, ciprofloxacin, nitrofurantoin, piperacil-
lin-tazobactam, trimethoprim-sulfamethoxazole, tetracycline, 
oxacillin, and vancomycin, as appropriate. Minimum inhibitory 
concentration (MIC) susceptibility interpretations were derived 
from CLSI M100 S-25 [6]. Antibiotic sensitivity percentages are 
reported as number of susceptible isolates divided by number 
of isolates tested. Susceptibility was reported overall and by 
sex and age (children: ≤17 years; adults: 18–64 years; and older 
adults: ≥65  years). Chi-square tests or Fisher exact tests were 
used to compare the overall prevalence of bacterial resistance 
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within and between agents tested and between age and sex 
groups.
RESULTS
A total of 78 078 urine culture susceptibility reports were 
included (Table  1). The majority of the urine cultures were 
obtained from female patients. The most frequently recovered 
isolates were Escherichia coli, 65.1%; Enterococcus spp., 11.9%; 
and Klebsiella pneumoniae, 10.0%. Among isolates recovered 
from females, the distribution was consistent with the overall 
study population. In men, the prevalence of E. coli was lower 
(40.3 %) relative to the overall population, whereas the prev-
alence of Enterococcus was higher (22.1%). In children, E. coli 
was the most prevalent isolate (73.7%), followed by Enterococcus 
(10.4%) and Proteus species (6.8%). The distribution of path-
ogens in adult (age 18–64  years) patients was similar to the 
overall population: E.  coli (68.5%), Enterococcus (11.2%), and 
K. pneumoniae (8.7%). In older adults, the prevalence of E. coli 
was lower (58.7%), whereas the prevalence rates of Enterococcus 
and Klebsiella were higher (12.2% and 12.8%, respectively).
Of all the isolates tested for nitrofurantoin sensitivity 
(n = 73 191), 90.4% were susceptible. Nitrofurantoin resistance 
was more commonly noted in males as compared with females 
(10.6% vs 9.1%, P < .001) and older adults as compared with all 
other ages combined (12.3% vs 8.1%, P  <  .001). High overall 
rates of susceptibility were reported for isolates tested for cefa-
zolin sensitivity (90.4%). However, due to the high prevalence of 
Enterococcus spp. (which is intrinsically resistant to cefazolin), 
cefazolin only has activity against 68.2% of the isolates. Only 
77.2% of all isolates tested (n = 67 711) were trimethoprim-sul-
famethoxazole susceptible. Resistance to trimethoprim-sul-
famethoxazole was more prevalent in men than women (26.3% 
vs 22.7%, P < .001) and in older adults than all other age groups 
combined (25.1% vs 22.1%, P < .001). Of the isolates tested for 
ciprofloxacin sensitivity (n = 68 709), 80.2% were susceptible. 
Resistance to ciprofloxacin was more frequent in males than 
females (35.0% vs 17.3%, P < .001) and in older adults than in 
all other ages combined (30. % vs 14.0%, P < .001). Additional 
data on pathogen-specific sensitivity overall and by sex and age 
groups are presented in Table 1. County-specific data are pro-
vided in the Supplementary Data.
DISCUSSION
The current Infectious Disease Society of America (IDSA) 
guidelines for acute uncomplicated cystitis recommend nitro-
furantoin, trimethoprim-sulfamethoxazole, or fosfomycin as 
firstline agents for treatment [2]. Overall, we found that bacter-
ial isolates in the outpatient setting in New York State were 90% 
sensitive in vitro to nitrofurantoin. The high probability of in 
vitro activity with nitrofurantoin is likely due to the high prev-
alence and susceptibility rates for E.  coli. Although the IDSA 
guidelines do not define a resistance prevalence threshold for 
assessing the appropriateness of nitrofurantoin for empiric use 
in treating acute uncomplicated cystitis, if we apply the tri-
methoprim-sulfamethoxazole threshold (20%, per the IDSA 
guidelines), our data support the utilization of nitrofurantoin 
in the New York State outpatient setting for this condition. 
In contrast, trimethoprim-sulfamethoxazole appears to have 
more limited utility as an empiric treatment regimen for acute 
uncomplicated cystitis as the overall prevalence of trimethop-
rim-sulfamethoxazole resistance exceeded 20%. Unfortunately, 
fosfomycin susceptibility data were unavailable in this data set 
as testing was not routinely performed. Given the limited activ-
ity of trimethoprim-sulfamethoxazole and ciprofloxacin for 
acute uncomplicated cystitis, it would be prudent for laborato-
ries to consider testing of fosfomycin in urinary isolates, espe-
cially for Escherichia coli and Enterococcus faecalis. In species 
other than Escherichia coli and Enteroccocus faecalis, the utility 
and validity of susceptibility results for fosfomycin have yet to 
be determined [6]. Importantly, recent data show that 1  day 
of fosfomycin is inferior to 5 days of nitrofurantoin for acute 
uncomplicated cystitis [7]. As such, fosfomycin should be used 
with caution when treating acute uncomplicated cystitis.
Susceptibility results from this study were also unfavorable to 
the empiric use of fluoroquinolones and β-lactam antibiotics. 
The overall prevalence of ciprofloxacin resistance was 19.8%, 
exceeding the IDSA-recommended 10% resistance threshold 
for empiric use. In light of the relatively high prevalence of fluo-
roquinolone resistance as well as growing concerns about fluo-
roquinolone-associated disability, our study supports the recent 
Food and Drug Administration recommendation to avoid 
empiric fluoroquinolone use unless no other alternative agents 
are available [7]. We also examined cefazolin as a surrogate for 
cephalexin susceptibility. When only Gram-negative bacterial 
species were isolated, cefazolin appeared to be an appropriate 
empiric agent. However, the utility of cefazolin as an empiric 
agent is less than favorable due to the high prevalence of 
Enterococcus, an organism that is intrinsically resistant to cefa-
zolin. Given that β-lactam medications require longer duration 
of treatment as compared with other therapies and are asso-
ciated with lower efficacy [8], our data suggest that β-lactam 
drugs should be considered as empiric agents only when poten-
tial benefits outweigh risks.
These data also indicate that the overall antimicrobial suscep-
tibility percentages of antimicrobials are significantly lower for 
individuals in the ≥65 age group compared with all other ages 
combined and among males of all ages compared with females. 
These findings highlight the need to not rely exclusively on 
overall susceptibility results and to consider sex, age, and prior 
urine culture results when selecting an agent for a given patient. 
As susceptibility rates varied by age and sex, subsequent adjust-
ment of therapy based on individualized culture and suscepti-
bility reports should be performed in an effort to promote use 
of narrow-spectrum antibiotics where possible.
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There are several caveats to be considered with respect to 
these findings. We did not include coagulase-negative staph-
ylococci in this analysis due to its questionable pathogenicity. 
However, our conclusions would be affected minimally by the 
inclusion of coagulase-negative staphylococci because coagu-
lase-negative staphylococci only accounted for 2% of isolates. 
Another potential limitation of this study is lack of data on 
clinical presentation of the patients. We did not determine 
whether these were symptomatic urinary tract infections or 
asymptomatic bacteriuria. Last, this study may overrepresent 
antimicrobial resistance rates as practitioners may only send 
urine cultures for patients with recurrent infections or treat-
ment failure.
Although these data are from New York State, there are 
several generalizable aspects of this study. First, this project 
highlights the framework for creating a regional antibiogram. 
Regional antibiograms are important tools that could be used 
by health departments and other regional authorities to help 
influence prescribing and/or track antimicrobial resistance 
for key pathogens. Second, New York State (especially Kings, 
Queens, New York, Bronx, and Richmond counties, the 5 New 
York City counties) is unique in that it has an incredibly high 
population density [9]. Along with antimicrobial utilization, 
population density has been shown to be associated with anti-
microbial resistance prevalence [10]. Hence, it stands to reason 
that New York State can be thought of as a regional bellwether 
for antimicrobial resistance.
In summary, we conducted a 1-year retrospective analysis 
of outpatient urine isolates collected from patients in New 
York State. Data indicated that nitrofurantoin has retained 
activity against many of the urinary pathogens since the pub-
lication of the 2011 IDSA guidelines and has a high preva-
lence of in vitro activity. In contrast, we found that the overall 
prevalence of resistance in bacterial urinary isolates exceeded 
the predefined IDSA empiric therapy thresholds of 20% for 
trimethoprim-sulfamethoxazole and 10% for fluoroquinolo-
nes, with resistance rates being highest in patients ≥65 years. 
These data highlight the need in outpatient settings for (1) 
urinary culture specimen submission, (2) antimicrobial stew-
ardship efforts, and (3) assembly of local susceptibility data 
to guide empiric therapy in acute uncomplicated cystitis. 
Finally, these data also support the desperate need for new 
oral antimicrobials to treat acute uncomplicated cystitis in 
the outpatient setting.
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